Company Profile
Cerus Corporation Stock Price, News & Catalysts
- Ticker:
- CERS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.34 USD (0.00%)
Close
Last updated: October 6, 2026
541M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, CERS was little changed and closed at $2.34. No new same-company headline was identified in the current news window.
Company overview
Blood-Safety Technology Company
Cerus develops products designed to reduce the risk of transfusion-transmitted infections and improve the availability of standardized blood components. Its customers include blood centers, hospitals, and transfusion-medicine providers in the United States and international markets.
INTERCEPT for Platelets and Plasma
The INTERCEPT Blood System treats donated platelets and plasma to inactivate a broad range of pathogens and contaminating donor white blood cells. These systems are approved in the United States and carry CE marking, supporting a recurring business based on disposable treatment kits and illumination devices.
INTERCEPT Fibrinogen Complex
In the United States, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen-reduced cryoprecipitated fibrinogen complex. The product provides fibrinogen replacement for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage.
Red Blood Cell Program
Cerus is developing an INTERCEPT system for red blood cells, the largest remaining major blood-component category not yet covered by its commercial platform. The program is under regulatory review in Europe and in late-stage clinical development in the United States.
Recurring Product and Government-Supported Model
Commercial revenue is driven primarily by treatment kits, finished blood products, and related system components. Government contracts, including support from BARDA, help fund development of the red blood cell system and other preparedness-related capabilities.
Future catalysts
- Phase 3 RedeS readout for the INTERCEPT Red Blood Cell system in 2026.
- FDA regulatory decision on the INT200 next-generation platelet illuminator in early 2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cerus Corporation (CERS)?
Cerus Corporation (CERS) most recently closed at 2.34 USD, a 0.00% move versus the previous session.
What is the market cap of Cerus Corporation (CERS)?
Cerus Corporation currently has a market capitalization of 541M USD on BioPharmSignal.
What does Cerus Corporation do?
Blood-Safety Technology Company Cerus develops products designed to reduce the risk of transfusion-transmitted infections and improve the availability of standardized blood components. Its customers include blood centers, hospitals, and transfusion-medicine providers in the United States and international markets. INTERCEPT for Platelets and Plasma The...
On which exchange is CERS stock listed?
Cerus Corporation (CERS) is associated with NASDAQ, United States, Biopharma.
What is Blood-Safety?
Blood-Safety Technology Company Cerus develops products designed to reduce the risk of transfusion-transmitted infections and improve the availability of standardized blood components.
Which conditions is Cerus Corporation targeting with Blood-Safety?
Blood-Safety Technology Company Cerus develops products designed to reduce the risk of transfusion-transmitted infections and improve the availability of standardized blood components. Its customers include blood centers, hospitals, and transfusion-medicine providers in the United States and international markets. INTERCEPT for Platelets and Plasma The...
How does Cerus Corporation describe recent progress with Blood-Safety?
Phase 3 RedeS readout for the INTERCEPT Red Blood Cell system in 2026. FDA regulatory decision on the INT200 next-generation platelet illuminator in early 2027.
What is Technology?
Blood-Safety Technology Company Cerus develops products designed to reduce the risk of transfusion-transmitted infections and improve the availability of standardized blood components.